---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-333820"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2026-08-05T11:05:06+00:00"
generated_at: "2026-08-05T11:10:56.974881+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Seres Q2 net income $4.6M on $25M Nestlé milestone; cash runway through Q1 2027

## Summary
- Net income of $4.6M vs net loss of $19.9M YoY; $25M gain from Nestlé milestone termination payment.
- Cash and equivalents $15.6M at June 30; expects additional $12.5M from Nestlé in Oct 2026; funds operations through Q1 2027.
- SER-155 in irEC: 80% (12/15) achieved immunosuppressive-free clinical response at day 15 in MSK IST.
- Terminated 200 Sidney Street lease; further reduces annual facility cash costs from 2027.
- Engaging partners for SER-155 (allo-HCT, irEC) and SER-603 (IBD); seeking capital to advance pipeline.

## SEC filing metadata
- accession: 0001193125-26-333820
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2026-08-05T11:05:06+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/0001193125-26-333820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/d124829d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-333820
- JSON: https://secwatch.observer/filing/0001193125-26-333820.json
- Plain text: https://secwatch.observer/filing/0001193125-26-333820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.